Identification of SPARC as a candidate target antigen for immunotherapy of various cancers

International Journal of Cancer

Volumn 127, Issue 6, 2010, Pages 1393-1403

  Inoue, Mitsuhiro ^a   Senju, Satoru ^a   Hirata, Shinya ^a   Ikuta, Yoshiaki ^a   Hayashida, Yuki ^a   Irie, Atsushi ^a   Harao, Michiko ^a   Imai, Katsunori ^a   Tomita, Yusuke ^a   Tsunoda, Takuya ^b   Furukawa, Yoichi ^b   Ito, Takaaki ^a   Nakamura, Yusuke ^b   Baba, Hideo ^a   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer immunotherapy; cDNA microarrays; CTL; HLA A24; SPARC; Tumor associated antigen

Indexed keywords

EPITOPE; HLA A24 ANTIGEN; OSTEONECTIN; OSTEONECTIN PEPTIDE; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77954542535     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25160     Document Type: Article

References (51)

1. Gattinoni L, Powell DJ, Rosenberg S, Restifo N. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.
2. Fang L, Lonsdorf A, Hwang S. Immunotherapy for advanced melanoma. J Invest Dermatol 2008;128:2596-605.
3. Copier J, Dalgleish A, Britten C, Finke L, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, et al. Improving the efficacy of cancer immunotherapy. Eur J Cancer 2009;45:1424-31.
4. Disis M, Bernhard H, Jaffee E. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373:673-83.
5. Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004;10:6437-48. (Pubitemid 39346538)
6. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006;12:2689-97. (Pubitemid 43752106)
7. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008;14:6487-95.
8. Jinawath N, Furukawa Y, Hasegawa S, Li M, Tsunoda T, Satoh S, Yamaguchi T, Imamura H, Inoue M, Shiozaki H, Nakamura Y. Comparison of geneexpression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 2004;23:6830-44. (Pubitemid 39280016)
9. Bradshaw A, Sage E. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001;107:1049-54. (Pubitemid 32422898)
10. Yan Q, Sage E. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999;47:1495-506.
11. Brekken R, Sage E. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001;19:816-27.
12. Inoue H, Matsuyama A, Mimori K, Ueo H, Mori M. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002;8:3475-9. (Pubitemid 35340724)
13. Wang C, Lin K, Chen S, Chan Y, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-30. (Pubitemid 40065522)
14. Maeng H, Song S, Choi D, Kim K, Jeong H, Sakaki Y, Furihata C. Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Lett 2002;184:117-21. (Pubitemid 34718113)
15. Guweidhi A, Kleeff J, Adwan H, Giese N, Wente M, Giese T, Büchler M, Berger M, Friess H. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005;242:224-34. (Pubitemid 41033439)
16. Prenzel K, Warnecke-Eberz U, Xi H, Brabender J, Baldus S, Bollschweiler E, Gutschow C, Hölscher A, Schneider P. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep 2006;15:1397-401.
17. Infante J, Matsubayashi H, Sato N, Tonascia J, Klein A, Riall T, Yeo C, Iacobuzio-Donahue C, Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25. (Pubitemid 350003021)
18. Bloomston M, Ellison E, Muscarella P, Al-Saif O, Martin E, Melvin W, Frankel W. Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Ann Surg Oncol 2007;14:211-7. (Pubitemid 44954291)
19. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995;64:70-5.
20. Madoz-Gúrpide J, López-Serra P, Martínez- Torrecuadrada J, Sánchez L, Lombardía L, Casal J. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 2006;5:1471-83.
21. Wiese A, Auer J, Lassmann S, Nährig J, Rosenberg R, Höfler H, Rüger R, Werner M. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 2007;31:282-95. (Pubitemid 47562633)
22. Kaiser S, Park Y, Franklin J, Halberg R, Yu M, Jessen W, Freudenberg J, Chen X, Haigis K, Jegga A, Kong S, Sakthivel B, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131. (Pubitemid 351916552)
23. Ledda F, Bravo A, Adris S, Bover L, Mordoh J, Podhajcer O. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108:210-4. (Pubitemid 27061034)
24. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc J, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999;189:46-52. (Pubitemid 29406818)
25. Menon P, Gutierrez J, Rempel S. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 2000;17:683-93.
26. Thomas R, True L, Bassuk J, Lange P, Vessella R. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-9. (Pubitemid 30159378)
27. Yamanaka M, Kanda K, Li N, Fukumori T, Oka N, Kanayama H, Kagawa S. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001;166:2495-9. (Pubitemid 33065342)
28. Iacobuzio-Donahue C, Argani P, Hempen P, Jones J, Kern S. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002;62:5351-7. (Pubitemid 35024612)
29. Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003;97:2412-9. (Pubitemid 36542479)
30. Massi D, Franchi A, Borgognoni L, Reali U, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30:339-44. (Pubitemid 29125155)
31. Podhajcer O, Benedetti L, Girotti M, Prada F, Salvatierra E, Llera A. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:691-705.
32. Clark C, Sage E. A prototypic matricellular protein in the tumor microenvironment - where there's SPARC, there's fire. J Cell Biochem 2008;104:721-32. (Pubitemid 351830824)
33. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, Sabatié E, Cano A, Garcia de Herreros A, Ballotti R, Tartare-Deckert S. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006;66:7516-23. (Pubitemid 44289206)
34. Alonso S, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo A, Sánchez L, Pajares R, Sánchez-Aguilera A, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007;67:3450-60. (Pubitemid 46724886)
35. Ikuta Y, Hayashida Y, Hirata S, Irie A, Senju S, Kubo T, Nakatsura T, Monji M, Sasaki Y, Baba H, Nishimura Y. Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci 2009;100:132-7.
36. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-21. (Pubitemid 39346558)
37. Ikuta Y, Nakatsura T, Kageshita T, Fukushima S, Ito S, Wakamatsu K, Baba H, Nishimura Y. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005;11:8079-88. (Pubitemid 41698751)
38. Tahara-Hanaoka S, Sudo K, Ema H, Miyoshi H, Nakauchi H. Lentiviral vector-mediated transduction of murine CD34(-) hematopoietic stem cells. Exp Hematol 2002;30:11-7. (Pubitemid 34061852)
39. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25. (Pubitemid 36629398)
40. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001;281:936-44. (Pubitemid 32917821)
41. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002;8:1731-9. (Pubitemid 34633728)
42. Inoue M, Senju S, Hirata S, Irie A, Baba H, Nishimura Y. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice. Immunol Lett 2009;126:67-72.
43. Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H, Fujita S, Tanimoto M, Harada M, Yasukawa M. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002;8:2626-31. (Pubitemid 34856350)
44. Karaki S, Kariyone A, Kato N, Kano K, Iwakura Y, Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993;37:139-42.
45. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004;23:2385-400. (Pubitemid 38496794)
46. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
47. Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, Kondo K, Kobayashi K, Yoshida M, Kaneko S, Kishida T, Kawakami S, Hosaka M, et al. SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol 2001;32:1064-70. (Pubitemid 33015666)
48. Tai I, Dai M, Owen D, Chen L. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005;115:1492-502. (Pubitemid 40814658)
49. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su G, Hruban R, Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22:5021-30. (Pubitemid 37026400)
50. Yang E, Kang H, Koh K, Rhee H, Kim N, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007;121:567-75. (Pubitemid 46986490)
51. Lane T, Sage E. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994;8:163-73. (Pubitemid 24067139)